Lovastatin Tablet
Product Images NDC 43063-692

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 43063-692). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063692 Label (43063692)

Label for Lovastatin 20 mg oral tablets, USP, marketed and packaged by PD-Rx Pharmaceuticals, Inc. and manufactured by Carlsbad Technology, Inc. The label indicates a package size of 180 tablets with an NDC of 43063-692-93 and includes storage instructions, warnings to keep out of reach of children, and a barcode and QR code.*

FDA Label Image

Structural Formula (Lov00 0004 01)

Chemical structure of Lovastatin. The image depicts the molecular formula representation of the active ingredient Lovastatin, showing its characteristic rings and functional groups relevant to its chemical composition.*

FDA Label Image

Table I (Lov00 0004 02)

A table titled 'The Effect of Other Drugs on Lovastatin Exposure When Both Were Co-administered' showing various drugs or grapefruit juice dosages given with lovastatin, the number of subjects, lovastatin dosage, and corresponding AUC ratios comparing lovastatin exposure with and without co-administration.*

FDA Label Image

Figure 1 (Lov00 0004 03)

A line graph titled 'Acute Major Coronary Events (Primary Endpoint)' comparing the proportion of participants without events over 6 years of follow-up between Lovastatin and placebo groups. The graph shows a lower event rate for Lovastatin, indicating a 37% risk reduction with statistical significance (p < 0.001).*

FDA Label Image

Table Vii (Lov00 0005 04)

A data table titled 'Table VII Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis' listing interacting agents such as strong CYP3A4 inhibitors, HIV protease inhibitors, Gemfibrozil, Cyclosporine, Danazol, Diltiazem, Dronedarone, Verapamil, Amiodarone, and grapefruit juice. It includes prescribing recommendations related to lovastatin contraindications, dosage limits, and avoidance advisories.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.